[go: up one dir, main page]

DK0893439T3 - Fremgangsmåde til fremstilling af et modificeret polypeptid indeholdende et polypeptid og et polyalkylenoxid - Google Patents

Fremgangsmåde til fremstilling af et modificeret polypeptid indeholdende et polypeptid og et polyalkylenoxid

Info

Publication number
DK0893439T3
DK0893439T3 DK98203166T DK98203166T DK0893439T3 DK 0893439 T3 DK0893439 T3 DK 0893439T3 DK 98203166 T DK98203166 T DK 98203166T DK 98203166 T DK98203166 T DK 98203166T DK 0893439 T3 DK0893439 T3 DK 0893439T3
Authority
DK
Denmark
Prior art keywords
polypeptide
preparing
polyalkylene oxide
peg
modified
Prior art date
Application number
DK98203166T
Other languages
English (en)
Inventor
Shmuel Zalipsky
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23335516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0893439(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enzon Inc filed Critical Enzon Inc
Application granted granted Critical
Publication of DK0893439T3 publication Critical patent/DK0893439T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Enzymes And Modification Thereof (AREA)
DK98203166T 1989-04-19 1990-04-19 Fremgangsmåde til fremstilling af et modificeret polypeptid indeholdende et polypeptid og et polyalkylenoxid DK0893439T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34092889A 1989-04-19 1989-04-19
PCT/US1990/002133 WO1990013540A1 (en) 1989-04-19 1990-04-19 Active carbonates of polyalkylene oxides for modification of polypeptides
EP90906698A EP0470128B2 (en) 1989-04-19 1990-04-19 Active carbonates of polyalkylene oxides for modification of polypeptides

Publications (1)

Publication Number Publication Date
DK0893439T3 true DK0893439T3 (da) 2005-09-05

Family

ID=23335516

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98203166T DK0893439T3 (da) 1989-04-19 1990-04-19 Fremgangsmåde til fremstilling af et modificeret polypeptid indeholdende et polypeptid og et polyalkylenoxid
DK90906698T DK0470128T4 (da) 1989-04-19 1990-04-19 Aktive polyalkylenoxidcarbonater til modifikation af polypeptider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK90906698T DK0470128T4 (da) 1989-04-19 1990-04-19 Aktive polyalkylenoxidcarbonater til modifikation af polypeptider

Country Status (10)

Country Link
EP (2) EP0470128B2 (da)
JP (1) JP2875884B2 (da)
AT (2) ATE181732T1 (da)
AU (1) AU5526690A (da)
CA (1) CA2053317C (da)
DE (2) DE69033192T3 (da)
DK (2) DK0893439T3 (da)
ES (2) ES2247656T3 (da)
HU (1) HUT64022A (da)
WO (1) WO1990013540A1 (da)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
AU1676992A (en) * 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
US5583114A (en) * 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
WO1996040792A1 (en) * 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
WO1996040791A1 (en) * 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU782580B2 (en) 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
CA2398668C (en) 2000-02-17 2010-06-15 3M Innovative Properties Company Delivery systems using preformed biodegradable polymer compositions and methods
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
BR0207576A (pt) 2001-02-27 2004-04-27 Maxygen Aps Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
SG177002A1 (en) 2001-10-10 2012-01-30 Novo Nordisk As Remodeling and glycoconjugation of peptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
DE60334983D1 (de) 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
PT1517710E (pt) 2002-06-21 2011-07-08 Novo Nordisk Healthcare Ag Glicoformas do factor vii peguilado
AU2003303595A1 (en) 2002-12-30 2004-07-29 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
WO2004103275A2 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
GB0314472D0 (en) * 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
CN102516386A (zh) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21衍生物
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
CA2553035A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
AU2005238015A1 (en) * 2004-04-21 2005-11-10 Alza Corporation Polymer conjugate releasable under mild thiolytic conditions
JP2008502788A (ja) 2004-06-08 2008-01-31 アルザ コーポレイション ４成分縮合反応による高分子コンジュゲートの調製
JP2008503217A (ja) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド 新規抗原結合ポリペプチド及びそれらの使用
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1771573A4 (en) 2004-07-21 2009-02-18 Ambrx Inc BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP2586456B1 (en) 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
SG158186A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0518661A2 (pt) 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
CN102732588B (zh) 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
EP2279756A2 (en) 2005-04-05 2011-02-02 Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. Method for shielding functional sites or epitopes on proteins
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
WO2006133089A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
MX2008002149A (es) 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101454461A (zh) 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
EP1797901A1 (en) 2005-12-16 2007-06-20 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
NZ571183A (en) 2006-03-13 2010-09-30 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
EP2213733A3 (en) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008030614A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
BRPI0717505B8 (pt) 2006-10-04 2021-05-25 Novo Nordisk As conjugado de peptídeo e formulação farmacêutica
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
RU2573587C2 (ru) 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
WO2010007626A1 (en) * 2008-07-14 2010-01-21 Biocon Limited A method of synthesizing a substantially monodispersed mixture of oligomers
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
EA201170493A1 (ru) 2008-09-26 2011-10-31 Амбркс, Инк. Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
HUE035168T2 (en) 2008-09-26 2018-05-02 Ambrx Inc Modified animal erythropoietin polypeptides and their applications
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
HUE037163T2 (hu) 2009-06-09 2018-08-28 Prolong Pharmaceuticals Llc Hemoglobin készítmények
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
SI3572091T1 (sl) 2010-08-17 2024-07-31 Ambrx, Inc., Modificirani polipeptidi relaksina in njihova uporaba
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2680875B1 (en) 2011-03-02 2019-10-23 Novo Nordisk Health Care AG Coagulation factor-targeting to tlt-1 on activated platelets
US9051562B2 (en) 2011-06-15 2015-06-09 Institut National De La Santé Et De La Recherche Médicale (Inserm) Polypeptides isolated from brevibacterium aurantiacum and their use for the treatment of cancer
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
EP3088005B1 (en) 2011-07-05 2019-01-02 biOasis Technologies Inc P97-antibody conjugates
US9884094B2 (en) 2012-05-01 2018-02-06 Novo Nordisk A/S Method of treating diabetes mellitus
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
CA2880162C (en) 2012-07-31 2023-04-04 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
HRP20190878T1 (hr) 2012-08-31 2019-07-26 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azidnu grupu
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
AU2013344464A1 (en) 2012-11-16 2015-05-21 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
CN105209497B (zh) 2013-03-15 2021-09-07 诺和诺德股份有限公司 能够特异性结合组织因子途径抑制物上的两个表位的抗体
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
AU2014354643B2 (en) 2013-11-27 2020-03-05 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
US12102689B2 (en) 2015-11-09 2024-10-01 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
WO2017180998A2 (en) 2016-04-15 2017-10-19 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
JP7109427B2 (ja) * 2016-06-01 2022-07-29 セルヴィエ アイピー ユーケー リミテッド ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
US10914728B2 (en) 2016-10-24 2021-02-09 Novo Nordisk A/S Bioassay for insulin formulations
WO2018111774A1 (en) 2016-12-12 2018-06-21 Becton, Dickinson And Company Water-soluble polymeric dyes
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
WO2019038420A1 (en) 2017-08-25 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOCLAST DISEASES
CN119286279A (zh) 2017-12-26 2025-01-10 贝克顿·迪金森公司 深紫外线可激发的水溶剂化聚合物染料
CN112384573A (zh) 2018-03-30 2021-02-19 贝克顿·迪金森公司 含侧基发色团的水溶性聚合染料
US20220162336A1 (en) 2018-07-22 2022-05-26 Bioasis Technologies, Inc. Treatment of lymphatic metastases
PL3849614T3 (pl) 2018-09-11 2024-04-22 Ambrx, Inc. Koniugaty polipeptydu interleukiny-2 i ich zastosowania
WO2020089743A1 (en) 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
WO2021048171A1 (en) 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
CN116744984A (zh) 2020-12-28 2023-09-12 达沃有限公司 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
WO2022200469A1 (en) 2021-03-24 2022-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) A dominant negative protein of rad51 for treating cancer
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
CN114965761B (zh) * 2022-05-17 2024-07-02 深圳赛保尔生物药业有限公司 聚乙二醇化蛋白药物中n-羟基琥珀酰亚胺的检测方法
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties
WO2024196805A1 (en) 2023-03-17 2024-09-26 Beckman Coulter, Inc. Benzothienopyrrole cyanine dyes
WO2025045915A1 (en) 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025064842A1 (en) 2023-09-21 2025-03-27 Beckman Coulter, Inc. Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
WO2025215206A1 (en) 2024-04-12 2025-10-16 Institut National de la Santé et de la Recherche Médicale Activator of primary cilia to treat cognitive dysfunctions or ciliopathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2631656C2 (de) * 1976-07-14 1983-02-10 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung eines Hydroxysuccinimidoester-Derivats zur Bindung von biologisch aktiven Proteinen aneinander und/oder an flüssige oder feste Trägerstoffe
CS204190B1 (en) † 1978-02-22 1981-03-31 Jaroslav Drobnik Activation method for hydrxyl groups containing insoluble carriers
DD219490A1 (de) † 1983-10-28 1985-03-06 Akad Wissenschaften Ddr Verfahren zur herstellung aktivierter traeger
YU144584A (en) † 1983-08-25 1987-06-30 Akad Wissenschaften Ddr Process for making n-(chlorocarbonyloxi)-s-norbornen-2,3-dicarboximide
JPS60156395A (ja) * 1984-01-17 1985-08-16 Mihama Hisaharu 修飾リパーゼ
DE3413904A1 (de) * 1984-04-13 1985-10-24 Hoechst Ag, 6230 Frankfurt Polymerisate auf basis von polyvinylencarbonat und/oder polyhydroxymethylen, verfahren zu ihrer herstellung und ihre anwendung
FR2574075B1 (fr) * 1984-12-04 1987-09-18 Poudres & Explosifs Ste Nale Procede de synthese d'esters actifs d'acides carboxyliques, nouveaux carbonates alpha-halogenes utiles pour cette synthese et leur mode d'obtention
JPH0757760B2 (ja) * 1987-06-05 1995-06-21 宇部興産株式会社 生体由来物質の固定化方法
DD260701A1 (de) † 1987-06-30 1988-10-05 Akad Wissenschaften Ddr Verfahren zur umesterung von aktiven unsymmetrischen kohlensaeurediester-gruppen an hydroxylgruppenhaltigen polymeren
DD261791A1 (de) † 1987-06-30 1988-11-09 Akad Wissenschaften Ddr Verfahren zur herstellung von carbonaten hydroxylgruppenhaltiger polymere
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides

Also Published As

Publication number Publication date
ES2136595T3 (es) 1999-12-01
DK0470128T3 (da) 2000-01-10
ES2136595T5 (es) 2004-04-01
DE69033192D1 (de) 1999-08-05
DK0470128T4 (da) 2003-12-01
EP0893439A1 (en) 1999-01-27
ATE300519T1 (de) 2005-08-15
WO1990013540A1 (en) 1990-11-15
CA2053317A1 (en) 1990-10-20
EP0893439B1 (en) 2005-07-27
ES2247656T3 (es) 2006-03-01
JPH04504872A (ja) 1992-08-27
EP0470128B2 (en) 2003-08-13
DE69033192T2 (de) 2000-03-09
JP2875884B2 (ja) 1999-03-31
EP0470128B1 (en) 1999-06-30
AU5526690A (en) 1990-11-29
DE69034200D1 (de) 2005-09-01
EP0470128A4 (en) 1992-09-16
DE69033192T3 (de) 2004-05-19
DE69034200T2 (de) 2006-05-24
CA2053317C (en) 1996-03-12
EP0470128A1 (en) 1992-02-12
HUT64022A (en) 1993-11-29
HU903628D0 (en) 1991-12-30
ATE181732T1 (de) 1999-07-15

Similar Documents

Publication Publication Date Title
DK0893439T3 (da) Fremgangsmåde til fremstilling af et modificeret polypeptid indeholdende et polypeptid og et polyalkylenoxid
DK1259563T3 (da) Fremgangsmåde til fremstillilng af 1-benzotriazolylcarbonat-estre af vandoplöselige polymerer
ATE123065T1 (de) Proteine und deren herstellung.
ATE134647T1 (de) Osteogene vorrichtungen
DK159723C (da) Tonede kontaktlinser og fremgangsmaade til fremstilling deraf
DK0402300T3 (da) Fremstilling i bakterier af gær og hæmoglobin og analoger dertil
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
DK0466174T3 (da) Hidtil ukendt fysiologisk aktivt svinepeptid (CNP-53)
AU4660789A (en) Polypeptide derivatives
DK491487A (da) Dna-sekvens til ekspressionering af biologisk aktivt faktor xiii og anvendelse af samme
FI913476A7 (fi) Konjugaattirokotteita, jotka sisältävät immunogeenista proteiinia, HIV-tyyppisiä peptidejä ja anionisia ryhmiä
EP0783003A4 (en) NEW POLYPEPTIDES
DK0490383T3 (da) Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf
KR950701347A (ko) 신규한 향종양성 사이토킨(A novel anti-neoplastic cytokine)
CA2088478A1 (en) Cloning and expression of a rhoptry associated protein of p. falciparum
PT92379A (pt) Metodo para a sintese de derivados polipeptidicos